FDA Approves Ultragenyx Gene Therapy for Rare Metabolic Disorder
RARE sits 55% above its 52-week low of $18.29.
Summary
The FDA approved Ultragenyx's gene therapy for a rare metabolic disorder, a major regulatory milestone that validates the company's gene therapy platform. This is the first approval for this specific therapy and comes just days before the DTX401 PDUFA date on August 23, suggesting the agency is moving favorably on the company's pipeline. The approval expands Ultragenyx's commercial portfolio and provides a new revenue stream in a high-value rare disease market. With a market cap of $2.6B and Q2 revenue of $214M, this approval could materially improve the company's growth outlook. Investors will watch for launch details and pricing, as well as the upcoming UX111 PDUFA on September 19.
At the time of this announcement, RARE was trading at $28.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $18.29 to $39.89. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.